INS and diabetes mellitus: DPP-4 inhibitors significantly reduced daily insulin requirements, particularly bolus doses, and postprandial blood glucose (by −34.40 mg/dL), especially in patients with a BMI < 25 kg/m2 and diabetes duration <3 years.